semaglutide fda submission approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Some people are overdosing on

doi: 10.1016/j.ajpath.2017.11.016 75 DereEDe Souza-SilvaMASpielerRELinJSOhtsuHHaasHLet al

If you miss a dose, take it as soon as possible

And people who are overweight or obese tend to need at the higher end of that range

Clinical evidence shows no contraindication between semaglutide and stable thyroid replacement therapy

[DOI] [PubMed] [Google Scholar] Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L

However, a reduction in cardiovascular risk has only been demonstrated thus far in cardiovascular outcome trials specifically designed in patients with obesity for semaglutide, whereas naltrexone plus bupropion did not show significant cardiovascular benefits